Compare HG & PBH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HG | PBH |
|---|---|---|
| Founded | 2013 | 1996 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.3B |
| IPO Year | 2023 | 2004 |
| Metric | HG | PBH |
|---|---|---|
| Price | $35.01 | $48.94 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 7 |
| Target Price | $38.14 | ★ $67.80 |
| AVG Volume (30 Days) | 333.8K | ★ 492.7K |
| Earning Date | 10-29-2026 | 11-05-2026 |
| Dividend Yield | ★ 5.81% | N/A |
| EPS Growth | ★ 51.23 | N/A |
| EPS | ★ 2.73 | 0.61 |
| Revenue | ★ $2,905,524,000.00 | $975,777,000.00 |
| Revenue This Year | $4.03 | $17.03 |
| Revenue Next Year | $2.31 | $6.06 |
| P/E Ratio | ★ $12.62 | $79.69 |
| Revenue Growth | 24.70 | ★ 36.77 |
| 52 Week Low | $22.66 | $42.62 |
| 52 Week High | $37.31 | $71.07 |
| Indicator | HG | PBH |
|---|---|---|
| Relative Strength Index (RSI) | 48.90 | 54.09 |
| Support Level | $33.22 | $47.61 |
| Resistance Level | $36.86 | $50.00 |
| Average True Range (ATR) | 0.97 | 1.41 |
| MACD | -0.14 | 0.05 |
| Stochastic Oscillator | 38.35 | 59.02 |
Hamilton Insurance Group Ltd is a specialty insurance and reinsurance company. It operates globally, with underwriting operations in London, Dublin, Bermuda, and the United States. It operates three principal underwriting platforms (Hamilton Global Specialty, Hamilton Select, and Hamilton Re) that are categorized into two reporting business segments: International and Bermuda.
Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.